Compare Franklin Resources, Inc. (BEN) vs Summit Therapeutics Inc (SMMT) Price & Performance

Franklin Resources (BEN) trades at $33.52, down 0.74% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $0.72, beating estimates, and achieved record AUM of $1.80 trillion as of July 31, 2026, driven by strong inflows and diversification efforts. Valuation ratios include a P/E of 22.69 and P/S of 1.85, while profitability metrics show a net income margin of 8.72%.

The outlook is positive with earnings beats and AUM growth, but risks include weaker ROE of 1.34% and net cash outflows. Analyst consensus price target is $36.50, suggesting potential upside, supported by a 'Buy' rating from 22% of analysts. Investors should monitor margin expansion and competitive pressures in the asset management sector.

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.